BCR-ABL–specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors

Key Points BCR-ABL–specific CTLs may be obtained by stimulation with peptides derived from BCR-ABL junctional region and alternative splicing. T-cell therapy with BCR-ABL–specific CTLs from healthy donors or patients mediates molecular or hematologic CR in patients with Ph+ ALL.